nafamostat has been researched along with Blood Poisoning in 4 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| " We analyzed therapeutic advantage of nafamostat, a broad-range protease inhibitor, on fibrinolysis in an animal sepsis model." | 7.73 | Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. ( Hryszko, T; Ihara, H; Inaba, K; Mogami, H; Suzuki, Y; Urano, T, 2006) |
| " We analyzed therapeutic advantage of nafamostat, a broad-range protease inhibitor, on fibrinolysis in an animal sepsis model." | 3.73 | Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. ( Hryszko, T; Ihara, H; Inaba, K; Mogami, H; Suzuki, Y; Urano, T, 2006) |
| "Nafamostat mesilate (NM), a synthetic protease inhibitor, is frequently used for the treatment of disseminated intravascular coagulation (DIC) in Japan." | 3.69 | Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. ( Abe, H; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1994) |
| "Whereas in DIC associated with trauma, since balance between coagulation and fibrinolysis collapses drastically in a short period, both anticoagulantion therapy and antifibrinolytic therapy can be utilized depending on clinical conditions." | 2.53 | [Anti DIC therapy]. ( Sakamoto, Y; Yahata, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yahata, M | 1 |
| Sakamoto, Y | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Kobayakawa, N | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Ogawa, T | 1 |
| Takemura, T | 1 |
| Aoyagi, T | 1 |
| Hryszko, T | 1 |
| Inaba, K | 1 |
| Ihara, H | 1 |
| Suzuki, Y | 1 |
| Mogami, H | 1 |
| Urano, T | 1 |
| Uchiba, M | 1 |
| Okajima, K | 1 |
| Abe, H | 1 |
| Okabe, H | 1 |
| Takatsuki, K | 1 |
1 review available for nafamostat and Blood Poisoning
| Article | Year |
|---|---|
[Anti DIC therapy].
Topics: Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzamidines; Disseminated Intravascular Coa | 2016 |
3 other studies available for nafamostat and Blood Poisoning
| Article | Year |
|---|---|
A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.
Topics: Aged; Aged, 80 and over; Antibodies; Benzamidines; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; | 2004 |
Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.
Topics: Animals; Benzamidines; Drug Interactions; Fibrinogen; Fibrinolysis; Guanidines; Interleukin-10; Lipo | 2006 |
Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity.
Topics: Amino Acid Sequence; Benzamidines; Blood Coagulation; Disseminated Intravascular Coagulation; Factor | 1994 |